Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Non-diabetic patients in these trials experienced benefits beyond weight reduction, including improved cardiovascular markers, better blood pressure control, and reduced inflammation
doi:10.4137/cmc.S26624 Probstfield JL, Boden WE, Anderson T, et al
[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk
Professor Sikirics research contributions include: Initial isolation and characterization of BPC-157 from human gastric secretions Extensive investigations of gastroprotective and tissue healing mechanisms Pioneering studies on musculoskeletal tissue repair including tendon and muscle healing Research on cardiovascular protective effects and vascular injury healing Over 400 published papers examining BPC-157s pleiotropic effects across organ systems His work has established BPC-157 as one of the most comprehensively studied components in peptide-based regenerative research, though human clinical validation remains absent
US$ 28.62
US$ 23.56
US$ 22.25
US$ 25.62
US$ 27.86
US$ 29.07
